Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
13.48
+0.57 (4.42%)
At close: Sep 9, 2025, 4:00 PM
13.49
+0.01 (0.07%)
Pre-market: Sep 10, 2025, 8:08 AM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $2.17M in the quarter ending June 30, 2025, a decrease of -72.84%. This brings the company's revenue in the last twelve months to $23.23M, down -35.86% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$23.23M
Revenue Growth
-35.86%
P/S Ratio
396.21
Revenue / Employee
$30,977
Employees
750
Market Cap
9.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
| Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ROIV News
- 1 day ago - Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire
- 6 days ago - Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript - Seeking Alpha
- 6 days ago - Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - GlobeNewsWire
- 25 days ago - Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 - GlobeNewsWire